New drug ADCT-701 for neuroendocrine and nerve tumors
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new drug called ADCT-701 for people with certain rare cancers (neuroendocrine tumors, adrenal cancer, or a type of nerve tumor) that have come back or spread. The drug is an antibody-drug conjugate, which works like a targeted missile to kill cancer cells while trying to spare healthy ones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a neuroendocrine tumor, adrenal cortical carcinoma, or malignant peripheral nerve sheath tumor that has spread or cannot be removed by surgery.
- You must have tried at least one standard treatment that stopped working or caused bad side effects.
- You must be 18 years or older and be able to do light daily activities (like desk work or light housework).
- Your blood counts (white blood cells, red blood cells, platelets) and liver/kidney function must meet certain minimum levels.
- You cannot have had major surgery, chemo, radiation, or other cancer treatment in the last 4 weeks.
- You must be willing to use effective birth control if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an immunotherapy drug (CTX-471) for people with a specific type of advanced neuroendocrine tumor that has grown after chemotherapy. The goal is to see if the drug can help shrink or control the tumor.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
This trial tests a new combination of drugs as the first treatment for people with advanced neuroendocrine cancer of the digestive system that has spread. It aims to see if the combination can shrink tumors and help people live longer.
This trial tests a new drug called SHR-A1904 for people with advanced neuroendocrine carcinoma that has grown after standard chemotherapy. The drug is given alone and may help shrink tumors or slow the disease.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.